Transient asymptomatic hepatitis B surface antigenemia following recombinant Recombivax B hepatitis B vaccine in a 42-year-old ESRD patient on maintenance hemodialysis

Macaulay Amechi Chukwukadibia Onuigbo1,3*, Catherine Kress4, Carol Webb3, Nneoma Agbasi2

1Mayo Clinic College of Medicine, Rochester, MN, USA
2North East London NHS Foundation Trust, UK
3Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI, USA
4Des Moines University, D.O. Class of 2018, USA

Implication for health policy/practice/research/medical education:
We report the rare phenomenon of transient hepatitis B surface antigenemia (HbSAgenemia) following preventative hepatitis B vaccination with Recombivax B vaccine. A misdiagnosis of a hepatitis B infection could lead to potentially harmful albeit unnecessary laboratory work up, unwarranted psychological stressors to the patient and family, and a feeling of anxiety and isolation. We reemphasize previous recommendations that patients who receive hepatitis B vaccinations should not be screened for HBsAg less than 4 weeks following a hepatitis B vaccination.

Article History:
Received: 8 September 2017
Accepted: 24 November 2017
ePublished: 14 December 2017

Article Type:
Case Report

Abstract

A 42-year old Caucasian end-stage renal disease (ESRD) male patient with past medical history including diabetes, hypertension, pulmonary hypertension (RVSP of 53 mm Hg) and tobacco use tested positive for hepatitis B surface antigen (HBsAg) after a routine blood screening test using an enzyme immunoassay (EIA) method. He however was otherwise asymptomatic for any symptoms of hepatitis. On further review, we confirmed that he had received an intramuscular dose of Recombivax (Merck) vaccine, 1 mL = 40 µg, 5 days previously. Follow up liver panel test was unremarkable with normal bilirubin and transaminases. Repeat serology testing at Mayo Clinic, Rochester the next day for a confirmatory neutralizing antibody assay test was negative for HBsAg. Furthermore, hepatitis B core IgM antibody, hepatitis B surface antibody, hepatitis B surface antibody qualitative, hepatitis B surface antibody quantitative test <0.1 (<8.0 mIU/mL), hepatitis B e antibody and hepatitis B core total antibody tests all subsequently returned negative. This is the second case of transient post-vaccination HbSAgenemia observed in our hemodialysis Unit in Northwestern Wisconsin in the last 7 years. Once again, as we posited in our 2010 report, we reemphasize previous recommendations that patients who receive hepatitis B vaccinations should not be screened for HBsAg less than 4 weeks following a hepatitis B vaccination.

Introduction

Hemodialysis exposes end-stage renal disease (ESRD) patients to significantly higher risks for hepatitis B virus (HBV) infection, a major public health scourge (1-4). Current US CDC guidelines and recommendations, last comprehensively revised in 2001, followed in US hemodialysis units, and simultaneously adhered to worldwide, among other recommendations, require monthly screening hepatitis B surface antigen (HBsAg) testing in all hemodialysis patients together with mandatory HBV vaccination of all hemodialysis patients (5-7). Furthermore, the usual hepatitis B vaccination protocol calls for a series of three recombinant HbSAg vaccines given intramuscularly at 0, 1 and 6 months respectively. In 2010, we reported in the journal Renal Failure, the rare phenomenon of transient HbSAgenemia two days following Engerix B (GlaxoSmithKline) vaccination in an 81-year old Caucasian woman on...
maintenance in-center outpatient hemodialysis (8). We just recently encountered a similar event, this time 5 days after Recombivax B (Merck) vaccination.

Case Presentation
A 42-year-old Caucasian male patient, on maintenance hemodialysis for end stage renal disease since December 2016 was admitted to the Hospitalist Service and underwent an elective placement of a left upper arm basilic vein transposition arteriovenous fistula on June 29, 2017. The patient has a history including diabetes, hypertension, pulmonary hypertension (RVSP of 53 mm Hg), smoker who started dialysis December 2016 via a tunneled right internal jugular vein dialysis catheter for symptomatic diabetic nephropathy for proteinuria ESRD, with anasarca and metabolic acidosis and had transferred to our unit in mid-March 2017. He had subsequently undergone a cardiac catheterization, elective in early June 2, 2017 with reported placement of a stent in the LAD. The AV fistula transposition was completed successfully on June 29, 2017 and he was soon confirmed to have a left foot non-healing osteomyelitis complicating peripheral arterial disease. Despite an antecedent left lower extremity angiogram with angioplasty and stenting carried out on July 1, 2017, he still ended up requiring a left lower extremity below knee amputation on July 6, 2017. In addition, a dark and painful necrotizing lesion involving the tip of the penis was reported and was suspected to represent some form of calciphylaxis. His calcium-based phosphate binder was discontinued and replaced with Sevelamer and he was then empirically started on intravenous sodium thiosulfate. He was discharged from the hospital to a Swing bed facility on July 12, 2017.

The next day, on July 13, in an outpatient dialysis unit, we were notified that he had tested positive for HBsAg after a routine blood screening test. He however was otherwise asymptomatic for symptoms of hepatitis. At the time of this notification, we were not immediately aware of the recent hepatitis B vaccination with Recombivax (Merck) vaccination that was given as an intramuscular injection (1 mL = 40 µg) on July 8, 2017. The following day, on July 14 a repeat blood sample was sent to Mayo Clinic, Rochester, for a confirmatory neutralizing antibody assay test which subsequently returned negative for HBsAg. The following additional hepatitis B-related tests all returned negative; hepatitis B core IgM antibody, hepatitis B surface antibody, hepatitis B surface antibody qualitative, hepatitis B surface antibody quantitative test <0.1 (<8.0 mIU/mL), hepatitis B e antibody and hepatitis B core total antibody. In the interim, however, as a precautionary measure, he was diazylized on a designated “other” hemodialysis machine. Further testing on July 17th revealed normal liver function test results for ALT 5 U/L (7-55 U/L), AST 14 U/L (8-48 U/L), total bilirubin 0.3 mg/dL (<1.2 mg/dL), and direct bilirubin <0.2 mg/dL (0.0-0.3 mg/dL). The elevated alkaline phosphatase, most likely from bone source secondary to renal osteodystrophic changes. Patient does not have a history of any blood transfusions.

On subsequent review, it became clear that the patient had received the first dose of the Recombivax vaccination on 1-7-17, the second dose, one month later, on 2-9-17 and the third index vaccination, 6 months later on 7-8-17, according to established protocol. In our dialysis units, routine blood screening for HbSAg is done locally with an enzyme immunoassay (EIA) method—GS HBsAg EIA 3.0 assay kit manufactured by Bio-Rad Laboratories (Redmond, WA, USA; US License No. 1109) (9). This is a state of the art third generation mouse monoclonal antibody-based EIA. However, any positive HBsAg tests are then confirmed by a neutralizing antibody assay, carried out at Mayo Clinic, Rochester (9). Of note, he had previously tested HbSAg negative in March 2017, in May 2017 and last in June 2017.

Discussion
Once again, we have demonstrated transient false positive HbSAg in an ESRD patient, this time, five days following Hepatitis B vaccination with Recombivax vaccine. In 2010, we reported a similar rare finding in an 81-year old ESRD female patient, two days following Engerix B vaccine (8).

The first cases of transient hepatitis B surface antigenemia (HBsAg) in adults following HBV immunization were reported in the 1990s (10-12). Ly et al, who demonstrated transient HBsAg in eight out of nine hemodialysis patients following HBV vaccine concluded that hemodialysis patients should not be screened for HBsAg within a week of HBV vaccination and that positive HBsAg within a month of hepatitis B vaccination must be interpreted with caution (13). To our knowledge, by 2009, all previous reports of transient positive HBsAg test results following Hepatitis B vaccination had followed Engerix B administration (10-14). Furthermore, our 2010 report also followed an Engerix B vaccine (8). In this report, the patient had received his third Recombivax B vaccine instead. Notably, both Engerix B and Recombivax B vaccines are both recombinant antigen derived vaccines that have no association with human blood or blood products. It remains unclear why the preponderance of reports of transient post-vaccination HbSAg in adults have followed the Engerix B vaccine (8-14).

Once again, as we posited in our 2010 report, we would want to reemphasize previous recommendations that patients who receive hepatitis B vaccinations should not be screened for HBsAg less than 4 weeks following a Hepatitis B vaccination (8,13). The longest reported interval between an Engerix B vaccination and a positive HBsAg test was eighteen days in an 17-year old potential American male blood donor (15). A misdiagnosis of a hepatitis B infection could lead to potentially harmful albeit unnecessary laboratory work up, unwarranted psychological stressors to the patient and family, and a feeling of anxiety and isolation for the patient as he will...
We report the rare phenomenon of transient hepatitis B surface antigenemia (HBsAg) following preventative hepatitis B vaccination with Recombivax B vaccine. A misdiagnosis of a hepatitis B infection could lead to potentially harmful albeit unnecessary laboratory work up, unwarranted psychological stressors to the patient and family, and a feeling of anxiety and isolation. We reemphasize previous recommendations that patients who receive Hepatitis B vaccinations should not be screened for HBsAg less than 4 weeks following a Hepatitis B vaccination.

Authors’ contribution
MACO: Conception, design, acquisition of data, data analysis, interpretation of data, literature review, drafting the article and final approval of manuscript. NA: Critical analysis, interpretation of data, literature review, drafting the article and final approval of manuscript. CW: Acquisition of data and final approval of manuscript. CK: Acquisition of data and final approval of manuscript.

Conflicts of interest
The authors declare no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors. The patient has given his informed consent regarding this case report.

Funding/Support
None.

References

Copyright © 2018 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.